Canopy Growth Corporation Announces Results of Special Shareholder Meeting
Acquisition of remaining interest in Canopy Health Innovations also voted on by its shareholders
SMITHS FALLS, ON, July 31, 2018 /CNW/ – Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth” or “the Corporation”) is pleased to announce the results of the Special Meeting of Shareholders (“Special Meeting”) which took place on July 30, 2018.
At the Special Meeting, Shareholders approved the Amended and Restated Omnibus Incentive Plan (the “OIP”), as described in the Corporation’s management information circular dated June 13, 2018 (the “Special Meeting Circular”). The detailed results of the votes for the approval of the OIP are provided below.
The resolution authorizing the Corporation to amend the Corporation’s Articles of Incorporation to divide the number of issued and outstanding common shares of the Corporation on the basis of a range between two-for one and three-for-one, at the discretion of the Board of Directors of the Corporation (the “Board”), as described in Special Meeting Circular (the “Share Split Resolution”) was also approved at the Special Meetings by more than two-thirds of the votes by way of a show of hands.
In accordance with the Share Split Resolution, the Board may, in its sole discretion, (i) implement the stock split within the range stated above or (ii) decide not to proceed with the stock split without further approval or notice to the shareholders.
If the Board decides to implement the share split, shareholders will be notified by way of press release and provided with more detailed information, including the final split ratio, at such time.
Canopy Growth is also pleased to announce the successful results of the special meeting of shareholders of Canopy Health Innovations Inc. (“Canopy Health” or “CHI”) held in Toronto, Ontario to approve Canopy Growth’s acquisition of all of its unowned interest in Canopy Health and Canopy Animal Health Inc. (“CAH”) by way of a plan of arrangement (the “Arrangement”), as previously announced by Canopy Growth on May 15, 2018. The shareholder of CAH has also approved the Arrangement.
The detailed results of the votes for the Arrangement are provided below:
The above excludes votes which may not be included in determining minority approval pursuant to the rules of Multilateral Instrument 61-101 – Protection of Minority Shareholders in Special Transactions. A total of 89.69% of the issued and outstanding common shares of CHI were voted at the meeting.
With the requisite shareholder approvals obtained, a final order of the Ontario Superior Court of Justice approving the Arrangement will be sought on August 2, 2018. Provided the final order is obtained and the satisfaction or waiver of all other conditions specified in the definitive agreement dated May 14, 2018, as amended, it is expected that the Arrangement will be completed on or about August 3, 2018.
The Arrangement, when completed, will bring the Company’s affiliated research arm fully into the broader Canopy Growth family.
Here’s to Future Growth.
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. Canopy Growth has operations in eight countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, Canopy Growth is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information visit www.canopygrowth.com
About Canopy Health Innovations
Canopy Health Innovations (Canopy Health) operates as an affiliated research arm of Canopy Growth Corporation and its subsidiaries. Canopy Health is soon to be owned fully by Canopy Growth and its business model is to engage simultaneously in numerous research areas, with a strict focus on the creation and enhancement of intellectual property, which is then retained exclusively on a first-priority basis. Canopy Health is focused on providing more in depth and advanced understanding of the cannabis plant and the potential medical uses for both humans and animals. This, combined with a more favourable regulatory system, and a global paradigm shift towards the normalization of cannabis, positions Canopy Health as an ideal company to conduct research, and develop safe, effective, natural medicines derived from cannabis.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.